|
|
January 19, 2012
Translating Pre-clinical Markers to Validated Assays and Their Application to Clinical Trials for the Pharma Industry |
Speakers for this Event: 
Dr. Peter Kerr, Product Development Team Manager, Almac 
Dr. Stephen Moore, Product Development Team Manager, Almac
|
|
 The development of personalized medicine is heavily dependant on the successful translation of biomarkers from bench to clinic. The pharma industry today is now routinely investing in biomarker strategies alongside their new compounds. The translation of these markers into clinically applicable tests and their use in clinical trials is a complex process.
This presentation will give examples of how Almac has done this, covering a range of topics including:
- Migration of assays across tissue types
- Migration of assays across platforms
- Development of assays into tests
- Biomarker clinical trial management
- Sample collection logistics
Details will be provided on the whole product development process with case studies highlighting the application of the developed tests for both retrospective and prospective analysis of samples from clinical trials. Examples will be shown of how this trial management and test delivery has been used to stratify and enrich early phase clinical trials.
|
| THIS PROGRAM IS INTENDED FOR |
- Senior scientists and clinical trials executives involved in companion diagnostics and biomarker strategies
- Pharma and biotechnology companies worldwide
|
|
|
Dr. Peter Kerr, Product Development Team Manager, Almac
Dr Peter Kerr is Product Development Team Manager at Almac’s Diagnostic business unit, developing prognostic biomarkers as part of the internal pipeline and working with pharmaceutical clients on the development of companion diagnostics.
Dr. Kerr studied at Cambridge University before doing postgraduate work at Edinburgh and Glasgow universities leading to a PhD. He worked on the functions of BRCA1 and BRCA2 in the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research before establishing and managing a microarray facility. He then worked as a programme manager with the NCRI Informatics Initiative before joining Almac Diagnostics in 2006. He was R&D Manager at the company and has now established the product development team at Almac Diagnostics business unit. |
|
|
Dr. Stephen Moore, Product Development Team Manager, Almac
Dr Stephen Moore is a Product Development Team Manager at Almac’s Diagnostic business unit, working with external pharmaceutical clients on the development of companion diagnostics and responsible for the management of other commercial genomic service and biomarker development projects.
Dr. Moore completed his PhD in radiation biology at the University of Ulster before entering industry and working on ELISA based protein chips to detect early stage cardiac damage. He joined Almac in 2003 working in bioinformatics and became genomic services manager in 2006. He is now focused on further establishing and developing commercial project management. |
| OUR XTALKS PARTNER FOR THIS EVENT |
|
|
|
Almac is a personalised medicine company focused on the discovery, development and delivery of biomarkers. We partner with the biopharmaceutical industry to provide biomarker discovery and development solutions. These range from pre-clinical biomarker discovery, through to full companion diagnostic development and clinical test delivery from our CLIA laboratory.
Our expert team consists of medical oncologists, molecular biologists and expert bioinformaticians. We have a portfolio of proprietary discovery arrays and extensive experience and expertise working with formalin fixed paraffin embedded (FFPE) tissue. We utilise this experience, expertise and innovative technologies to develop diagnostics for our partners as well as our own pipeline of molecular diagnostics. |
| |